Table 8.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1996 to 2005

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 860 853 972 941 915 891 905 871 881 903
Tx with Follow-up Immunosuppression Info 773 781 870 859 840 818 819 784 782 810
Corticosteroids Any in Category 100.0% 99.9% 99.7% 99.5% 95.6% 93.4% 89.4% 81.9% 75.7% 73.5%
Steroids 100.0% 99.9% 99.7% 99.5% 95.6% 93.4% 89.4% 81.9% 75.7% 73.5%
Cyclosporine Any in Category 61.7% 48.7% 36.2% 31.1% 23.0% 17.0% 13.4% 11.9% 8.7% 7.2%
Cyclosporin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0%
Sandimmmune 12.9% 8.6% 4.1% 5.0% 3.1% 1.8% 1.3% 0.6% 0.5% 0.1%
Neoral 48.8% 40.1% 32.1% 25.8% 18.7% 12.2% 8.8% 9.2% 6.8% 5.3%
Gengraf 0.0% 0.0% 0.0% 0.2% 1.2% 2.8% 3.2% 2.0% 1.4% 1.7%
Eon 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%
Tacrolimus Any in Category 51.0% 62.4% 75.3% 80.7% 84.3% 89.4% 89.9% 87.6% 87.6% 93.5%
Tacrolimus 51.0% 62.4% 75.3% 80.7% 84.3% 89.4% 89.9% 87.6% 87.6% 93.5%
Antimetabolites Any in Category 94.0% 96.0% 96.8% 95.7% 87.6% 80.4% 82.3% 82.5% 86.3% 86.5%
Mycophenolate Mofetil 72.1% 82.1% 85.1% 87.4% 81.3% 77.5% 79.9% 80.4% 79.8% 75.4%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.7% 10.0%
Azathioprine 22.0% 14.0% 11.7% 8.3% 6.3% 2.9% 2.4% 2.2% 1.7% 0.9%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.2%
Cytoxan 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitors Any in Category 0.0% 0.0% 2.0% 5.2% 21.0% 31.2% 27.6% 27.6% 24.3% 22.2%
Sirolimus 0.0% 0.0% 0.9% 4.8% 20.5% 31.1% 27.6% 27.6% 24.3% 22.2%
Everolimus 0.0% 0.0% 1.0% 0.5% 0.5% 0.1% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.